{{Drugbox | IUPAC_name = 4-{[4-({4-[(E)-2-cyanoethenyl]-2,6-dimethylphenyl}
amino)pyrimidin-2-yl]amino}benzonitrile | image = Rilpivirine.svg | image2 = Rilpivirine3D.PNG | CAS_number = 500287-72-9 | ATC_prefix = | ATC_suffix = | PubChem = 6451164 | DrugBank = | C=22|H=18|N=6 | molecular_weight = 366.42 g/mol | bioavailability = | protein_bound = | metabolism = | elimination_half-life = 38 hours | excretion = | pregnancy_AU = | pregnancy_US = | pregnancy_category= | legal_AU = | legal_CA = | legal_UK = | legal_US = | legal_status = | routes_of_administration = Oral }} Rilpivirine (TMC278) is an investigational new drug, developed by Tibotec, for the treatment of HIV infection. It is a second-generation non-nucleoside reverse transcriptase inhibitor (NNRTI) with higher potency, longer half-life and reduced side-effect profile compared with older NNRTIs, such as efavirenz. It entered phase III clinical trials on April 2008, with an estimated study completion date on August, 2010. Like etravirine, a second-generation NNRTI approved in 2008, rilpivirine is a diarylpyrimidine (DAPY).

References